
ALT The financial and commercial growth of the Chinese BioTech and Pharma ecosystem is undisputed and is constantly growing in an unprecedented pace. This excellent FT chart - based on biopharma data gatherer sleuth insights, shows that so far this year, Pharma companies from around the world have signed licensing deals with Chinese companies worth 110 billion dollars - which represent a 20 billion dollars growth Year over year , with 3 more months remaining in 2026!

ALT This short and interesting article - by FT’s wonderful China Tech correspondent - Eleanor Olcott and William Sandlund FT’s Asia market correspondent, tells the story of maybe the most important and fascinating development in the BioTech and Pharma global ecosystem over the past few years - the unprecedented growth of the Chinese BioTech sector, the way in which it has successfully transformed itself from a manufacturing-oriented industry into a cutting-edge innovative hub and the reforms made by the Chinese government in the mid-2010’s which allowed all of this exponential growth to happen. 2025 has been a breaking-record year - the sixth consecutive year in a row - with 93 overseas licensing deals worth 85 billion dollars in just the first 8 months! This is even more impressive considering the fact that ten years ago China almost didn’t have a BioTech sector to talk about and now it’s a global BioTech powerhouse!




























